Design and optimization of a large scale biopharmaceutical facility using process simulation and scheduling tools

Pharmaceutical Engineering

Volumn 30, Issue 2, 2010, Pages

  Toumi, Abdelaziz ^a   Jürgens, Christian ^b   Jungo, Carmen ^a   Maier, Bernd A ^b   Papavasileiou, Victor ^c   Petrides, Demetri P ^d  

^a MERCK SERONO S A   (Switzerland)

^b MERCK KGAA   (Germany)

^c Avantium Chemicals BV   (Netherlands)

^d Intelligen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; BATCH PROCESS; BIOREACTOR; CASE STUDY; CELL EXPANSION; COMPUTER AIDED DESIGN; COST BENEFIT ANALYSIS; CROHN DISEASE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURIFICATION; DRUG SYNTHESIS; ENVIRONMENTAL IMPACT ASSESSMENT; EQUIPMENT DESIGN; EUROPE; GRAFT REJECTION; HUMAN; INFORMATION SYSTEM; INVESTMENT; MANPOWER; NEOPLASM; PHARMACEUTICAL ENGINEERING; PROCESS DEVELOPMENT; PROCESS MODEL; PROCESS OPTIMIZATION; PSORIASIS; RHEUMATOID ARTHRITIS; SCHEDULING TOOL; UNITED STATES; VALIDATION PROCESS; VIRUS INACTIVATION;

EID: 77953916038     PISSN: 02738139     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Petrides, D., Koulouris, A., and Lagonikos, P., "The Role of Process Simulation in Pharmaceutical Process Development and Product Commercialization," Pharmaceutical Engineering, January/February 2002, Vol. 22, No. 1, www.ispe.org.
2. Petrides, D., Koulouris, A., and Siletti, C., "Throughput Analysis and Debottlenecking of Biomanufacturing Facilities, A Job for Process Simulators," BioPharm, August 2002.
3. Petrides, D., and Siletti, C., "The Role of Process Simulation and Scheduling Tools in the Development and Manufacturing of Biopharmaceuticals, Proceedings of the 2004 Winter Simulation Conference, Ingalls, R.G., Rossetti, M. D., Smith, J. S., and Peters, B. A., eds., pp. 2046-2051.
4. Tan, J., Foo, D.C.Y., Kumaresan, S., and Aziz, R.A., " Debottlenecking of a Batch Pharmaceutical Cream Production," Pharmaceutical Engineering, July/August 2006, Vol. 26 No. 4, pp. 72-82, www.ispe.org.
5. Pharmaceutical Research and Manufacturers of America, Biotechnology Research Continues to Bolster Arsenal Against Disease with 633 Medicines in Development, PhRMA 2008 survey, www.phrma. org.
6. Walsh, G., "Biopharmaceutical Benchmarks 2006," Nat. Biotech, 24(7) 2006:769-775.
7. Farid, S.S., "Established Bioprocesses for Producing Antibodies as a Basis for Future Planning," Advances in Biochemical Engineering/ Biotechnology, (2006) 101: 1-42, published online 8 June 2006.
8. Pavlou, A.K., Belsey, M.J., "The Therapeutic Antibodies Market to 2008," European Journal of Pharmaceutics and Biopharmaceutics, 59(3) 2005:389-396.
9. Jagschies, G., "Where is Biopharmaceutical Manufacturing Heading?," BioPharm International, 21(10), October 2008.
10. Farid, S.S., "Economic Drivers and Trade-Offs in Antibody Purification Processes," BioPharm International, http:// biopharminternational.findpharma.com/biopharm/Downstream+Processing/ Economic-Drivers-and-Trade-Offs-in-Antibody-Purifi/ArticleStandard/Article/ detail/633295, 2 October 2009.
11. Low, D., O'Leary, R., Pujar, N.S., "Future of Antibody Production," Journal of Chromatography, B 848(1), 2007:48-63.
12. Parshall, J., Lamb, L., Applying S88 - Batch Control from a User's Perspective, Instrument Society of America (ISA), Research Triangle Park, North Carolina, USA, 2000.